Skip to content

Study · Randomized controlled trial · n = 401 · 2024

5 results

Clinical characteristics affecting weight loss in an East Asian population receiving semaglutide: A STEP 6 subgroup analysis.

Kadowaki T, Lee SY, Ogawa W, Nishida T, Overvad M, Tobe K, Yamauchi T, Lim S

Obesity research & clinical practice1 Nov 2024Cited by 5 (Europe PMC)

PMID39824696 (opens in a new tab)DOI10.1016/j.orcp.2025.01.002 (opens in a new tab)PepBankPUB-39824696
Publisher pagePubMedAsk about this study
Jump to 5 results

Summary

ObjectiveTo explore the effects of semaglutide versus placebo on body weight (BW) by subgroups of baseline characteristics.MethodsIn STEP 6, Japanese and Korean adults with overweight or obesity were randomized to subcutaneous semaglutide 2.4 mg, semaglutide 1.7 mg, or placebo for 68 weeks. A subset of Japanese participants with type 2 diabetes (T2D) was also included. In this post-hoc analysis, change from baseline in BW (%) was assessed by subgroups of baseline characteristics including baseline BW, body mass index, age, sex, glycemic status, dyslipidemia, and hypertension.ResultsOf 401 participants (148 female and 253 male) included, the estimated mean change in BW was clinically relevant across all subgroups for semaglutide 2.4 mg, ranging from -9.40 % to -16.42 %. Estimated treatment differences also favored both semaglutide doses versus placebo. Significant treatment-by-subgroup interactions were observed for sex with semaglutide 1.7 mg and 2.4 mg versus placebo at week 68 (p = 0.0008 and p = 0.0005, respectively). Significant treatment-by-subgroup interactions were also observed for presence of T2D and dyslipidemia at baseline, for semaglutide 2.4 mg versus placebo only (p = 0.0381 and p = 0.0181, respectively).ConclusionsSemaglutide reduces BW in a wide demographic of people with a range of weight-related comorbidities in an East Asian population.
CC BYText from Europe PMC. Highlighted sentences are the source of results.

Results from this study5

5 results from studies that gave the peptide. 5 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In Japanese and Korean adults with overweight or obesity, estimated treatment differences in body weight favored both semaglutide doses over placebo across subgroups.

    In plain wordsIn Japanese and Korean adults with overweight or obesity, both semaglutide doses lowered weight more than placebo in all subgroups.

    Peptide
    Semaglutide
    Outcome
    DecreaseTreatment difference in body weight versus placebo by subgroup
    Study

    n = 401

    Comparator
    Placebo
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    1.7 mg and 2.4 mg · subcutaneous · 68 weeksAs given in this study (human).

    Source sentences

    Summary
    Estimated treatment differences also favored both semaglutide doses versus placebo.
    1 context sentence
    Summary · context
    In STEP 6, Japanese and Korean adults with overweight or obesity were randomized to subcutaneous semaglutide 2.4 mg, semaglutide 1.7 mg, or placebo for 68 weeks.
  2. 02HumanRandomized controlled trialEfficacy outcome

    In Japanese and Korean adults with overweight or obesity, the weight effect of semaglutide 1.7 mg and 2.4 mg versus placebo differed significantly by sex at week 68.

    In plain wordsIn Japanese and Korean adults with overweight or obesity, the weight effect of semaglutide compared with placebo differed between men and women.

    Peptide
    Semaglutide
    Outcome
    Not applicableTreatment-by-sex interaction on body weight
    Study

    n = 401

    Comparator
    Placebo
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    1.7 mg and 2.4 mg · subcutaneous · 68 weeksAs given in this study (human).

    Measurements

    P interaction
    0.0008
    1.7 mg, sex
    P interaction
    0.0005
    2.4 mg, sex

    Source sentences

    Summary
    Significant treatment-by-subgroup interactions were observed for sex with semaglutide 1.7 mg and 2.4 mg versus placebo at week 68 (p = 0.0008 and p = 0.0005, respectively).
    1 context sentence
    Summary · context
    In STEP 6, Japanese and Korean adults with overweight or obesity were randomized to subcutaneous semaglutide 2.4 mg, semaglutide 1.7 mg, or placebo for 68 weeks.
  3. 03HumanRandomized controlled trialEfficacy outcome

    In Japanese and Korean adults with overweight or obesity, semaglutide 2.4 mg reduced body weight in all baseline subgroups, with estimated mean changes of -9.40% to -16.42%.

    In plain wordsIn Japanese and Korean adults with overweight or obesity, semaglutide 2.4 mg lowered body weight in every subgroup examined.

    Peptide
    Semaglutide
    Outcome
    DecreaseBody weight change across baseline subgroups
    Study

    n: not reported in source

    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    2.4 mg · subcutaneous · 68 weeksAs given in this study (human).

    Measurements

    Body weight change
    −9.4%
    subgroup, lowest
    Body weight change
    −16.42%
    subgroup, highest

    Source sentences

    Summary
    Of 401 participants (148 female and 253 male) included, the estimated mean change in BW was clinically relevant across all subgroups for semaglutide 2.4 mg, ranging from -9.40 % to -16.42 %.
    1 context sentence
    Summary · context
    In STEP 6, Japanese and Korean adults with overweight or obesity were randomized to subcutaneous semaglutide 2.4 mg, semaglutide 1.7 mg, or placebo for 68 weeks.
  4. 04HumanRandomized controlled trialEfficacy outcome

    In Japanese and Korean adults with overweight or obesity, the weight effect of semaglutide 2.4 mg versus placebo differed significantly by presence of type 2 diabetes.

    In plain wordsIn Japanese and Korean adults with overweight or obesity, the weight effect of semaglutide 2.4 mg compared with placebo differed by diabetes status.

    Peptide
    Semaglutide
    Outcome
    Not applicableTreatment-by-type 2 diabetes interaction on body weight
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    2.4 mg · subcutaneous · 68 weeksAs given in this study (human).

    Measurements

    P interaction
    0.0381
    2.4 mg, T2D

    Source sentences

    Summary
    Significant treatment-by-subgroup interactions were also observed for presence of T2D and dyslipidemia at baseline, for semaglutide 2.4 mg versus placebo only (p = 0.0381 and p = 0.0181, respectively).
    1 context sentence
    Summary · context
    In STEP 6, Japanese and Korean adults with overweight or obesity were randomized to subcutaneous semaglutide 2.4 mg, semaglutide 1.7 mg, or placebo for 68 weeks.
  5. 05HumanRandomized controlled trialEfficacy outcome

    In Japanese and Korean adults with overweight or obesity, the weight effect of semaglutide 2.4 mg versus placebo differed significantly by presence of dyslipidemia.

    In plain wordsIn Japanese and Korean adults with overweight or obesity, the weight effect of semaglutide 2.4 mg compared with placebo differed by cholesterol status.

    Peptide
    Semaglutide
    Outcome
    Not applicableTreatment-by-dyslipidemia interaction on body weight
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    2.4 mg · subcutaneous · 68 weeksAs given in this study (human).

    Measurements

    P interaction
    0.0181
    2.4 mg, dyslipidemia

    Source sentences

    Summary
    Significant treatment-by-subgroup interactions were also observed for presence of T2D and dyslipidemia at baseline, for semaglutide 2.4 mg versus placebo only (p = 0.0381 and p = 0.0181, respectively).
    1 context sentence
    Summary · context
    In STEP 6, Japanese and Korean adults with overweight or obesity were randomized to subcutaneous semaglutide 2.4 mg, semaglutide 1.7 mg, or placebo for 68 weeks.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    11 Oct 2026, 00:04 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:06 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.